title: Interval cytoreduction in advanced ovarian cancer: Santa Casa São Paulo experience.
abstract: OBJECTIVE
  To analyze the interval cytoreduction in patients with advanced ovarian cancer.
  
  
  METHODS
  A prospective study was carried out with 25 patients with advanced ovarian cancer (stages IIIC or IV) who underwent interval cytoreduction. Nonresectability criteria were based on the ones from Gustave-Rousy Institute. After induction chemotherapy and rapprochement we evaluated the rates of optimal surgery and the morbidity and mortality of the procedure in addition to the overall survival at two years.
  
  
  RESULTS
  optimal cytoreduction was possible in 17 patients (68%) with morbidity and mortality from 8% to 4%. The overall survival at two years was 68%.
  
  
  CONCLUSIONS
  The interval cytoreduction is an alternative therapy in advanced ovarian cancer, allowing optimal cytoreduction opportunity to patients suffering from unresectable disease, with acceptable morbidity and mortality.
authors.affiliation: Clínica de Oncologia Pélvica, DOGI, Irmandade da Santa Casa de São Paulo, SP, BR. rozenowicz.r@uol.com.br
authors.forename: Renato de Lima
authors.initials: Rde L
authors.lastname: Rozenowicz
authors.forename: Roberto Euzébio Dos
authors.initials: RE
authors.lastname: Santos
authors.forename: Fabio Francisco Oliveira
authors.initials: FF
authors.lastname: Rodrigues
authors.forename: Ricardo da Fonseca
authors.initials: Rda F
authors.lastname: Nadais
authors.forename: Adriana Bitencourt
authors.initials: AB
authors.lastname: Campaner
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Aoki
mesh_terms: D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D011446:Prospective Studies; D015996:Survival Rate